The filing provides no current revenue or earnings data, only forward-looking operational metrics. Monitor future 6-K or 20-F filings for actual revenue recognition from the CDMO contract and cash burn rate. The extended runway reduces near-term financing risk but dilution from equity raises remains a concern.
Price Chart
Executive Summary
Scinai CEO issued a shareholder letter detailing a $5.1M committed CDMO agreement, a $5.3M combined net financing, and an extended operating runway to late 2027 (potentially Q3 2028). Committed Customer Orders grew to $8.1M from $1.9M at year-end 2025, but the company acknowledges dilution from equity financings and provides no current revenue or earnings figures.
Key Facts
- New CDMO agreement with a U.S.-based Nasdaq-listed biopharma includes ~$5.1M in committed base service fees.
- Committed Customer Orders stood at ~$8.1M as of Oct 20, 2026, up from $1.9M at year-end 2025 (>300% increase).
- Combined net proceeds from SEPA drawdown and private placement/warrant exercise total ~$5.3M.
- Management estimates operating runway to late 2027, potentially extending to Q3 2028 if later project phases are activated.
- Potential uncommitted clinical manufacturing work has an indicative value of ~$5.85M, bringing total opportunity to >$10M.
- CEO explicitly acknowledges dilution from equity financings.
Financial Impact
~$5.3M net cash raised; ~$8.1M in Committed Customer Orders; ~$5.1M base CDMO contract; total opportunity >$10M including uncommitted phases.
Risk Factors
- CDMO contract is subject to performance and termination-for-convenience clauses; uncommitted phases require separate activation.
- Equity financings have caused dilution; further dilution may occur if additional capital is needed.
- No current revenue or profitability data provided; runway estimates depend on sales, collections, and execution.
- Customer concentration risk — single U.S.-based biopharma customer for the new agreement.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-110869 |
| Document: ea0309143-6k_scinai.htm | 0001213900-26-110869 |
| Document: 0001213900-26-110869-index-headers.html | 0001213900-26-110869 |
| Document: 0001213900-26-110869-index.html | 0001213900-26-110869 |
| Document: 0001213900-26-110869.txt | 0001213900-26-110869 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 6-K | $0.6813 | awaiting T+60 | — | $0.5310 (−22.06%) |
Oct 16, 2026 11d ago | 6-K | $0.7520 | awaiting T+60 | — | $0.5310 (+29.39%) |
Oct 16, 2026 11d ago | Press Release | $0.7524 | awaiting T+60 | — | $0.5310 (+29.43%) |
Oct 15, 2026 12d ago | 6-K | $0.9015 | awaiting T+60 | — | $0.5310 (+41.10%) |
Oct 13, 2026 14d ago | 6-K | $1.23 | awaiting T+60 | — | $0.5310 (−56.83%) |
Oct 6, 2026 21d ago | EFFECT | $1.22 | awaiting T+60 | — | $0.5310 (+56.48%) |
Sep 21, 2026 5w ago | 6-K | $1.69 | awaiting T+60 | — | $0.5310 (−68.58%) |
Aug 26, 2026 8w ago | 6-K | $2.87 | awaiting T+60 | — | $0.5310 (+81.50%) |
Aug 19, 2026 9w ago | 6-K | $0.2740 | awaiting T+60 | — | $0.5310 (−93.80%) |
Jun 17, 2026 18w ago | 6-K | $0.3370 $0.2440 | ▼ −27.60% | ▼ −30.28% | $0.5310 (+57.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers